New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
November 12, 2012
17:02 EDTSQNMSequenom CMM's announces results of RetnaGene AMD
Sequenom announced its wholly-owned subsidiary, Sequenom Center for Molecular Medicine, presented results from a study of its RetnaGene AMD laboratory-developed test to predict risk of disease progression during the 2012 Joint Meeting of the American Academy of Ophthalmology and the Asia-Pacific Academy of Ophthalmology in Chicago. This Sequenom CMM laboratory-developed genetic test combines patient disease stage with patient genetic variation to evaluate the risk of a patient with early or intermediate AMD to progress to advanced choroidal neovascularization, or CNV, disease within 2, 5, and 10 years. CNV is the most common form of 'wet' advanced age-related macular degeneration, or AMD, in which new blood vessels in the eye leak fluid, compromising central vision. Advanced disease impacts approximately 10% of AMD patients, but is associated with 90 percent of vision loss in AMD.
News For SQNM From The Last 14 Days
Check below for free stories on SQNM the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
August 19, 2014
11:32 EDTSQNMLabCorp prenatal test a negative for Sequenom, says Maxim
Maxim views LabCorp's (LH) announcement today that it will begin offering the informaSeq prenatal test as a long-term negative for Sequenom (SQNM) due to increased competition. The news is also negative for Illumina (ILMN) and PerkinElmer (PKI), who both offer Non-Invasive Prenatal Tests, Maxim adds. The firm recommends buying shares of LabCorp and keeps a Buy rating on the name with a $130 price target.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use